- Stocks
- Pharma & Healthcare
- Dishman Carbogen Amcis
Dishman Carbogen Amcis share price
NSE: DCALPharma & HealthcareBiotechnology
Dishman Carbogen Amcis at a glance
Dishman Carbogen Amcis (NSE: DCAL) closed at ₹141.95 on 22 Oct 2026, up 0.07% on the day. With a market capitalisation of ₹2,226 Cr, it ranks 1100th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
At its last close the stock traded at 22.8× trailing earnings, against a return on equity of 1.5% in FY26. Over the past year the share price has fallen 49.1%. Its 52-week range is ₹128.50 (30 Mar 2026) to ₹303.00 (31 Oct 2025); the last close is 53.2% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹851 Cr (+18.9% year on year) and net profit ₹22 Cr (−49.5%), on a consolidated basis. Promoters held 59.32% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹2,226 CrRank 1100 on NSE
- P/E (trailing)
- 22.8×
- Price to book
- 0.31×FY26
- EPS (TTM)
- ₹6.21to Q4 FY26
- ROE
- 1.5%FY26
- ROCE
- 2.9%FY26
- Debt to equity
- 0.42FY26
- Net profit margin
- 3.3%FY26
- Book value / share
- ₹425.82FY26
- 52-week high
- ₹303.0031 Oct 2025
- 52-week low
- ₹128.5030 Mar 2026
- 1-year return
- −49.1%
- RSI (14-day)
- 27.8
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.07% | −7.2% | −17.0% | −23.3% | −49.1% |
Dishman Carbogen Amcis quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹524 Cr | ₹789 Cr | ₹682 Cr | ₹716 Cr | ₹708 Cr | ₹653 Cr | ₹720 Cr | ₹851 Cr |
| Revenue YoY | −27.6% | +34.5% | +4.8% | +9.4% | +35.2% | −17.3% | +5.5% | +18.9% |
| Net profit | −₹78 Cr | ₹33 Cr | ₹5 Cr | ₹43 Cr | ₹23 Cr | ₹65 Cr | −₹13 Cr | ₹22 Cr |
| Net profit YoY | −556.3% | — | — | — | — | +97.2% | −380.1% | −49.5% |
| Net margin | −14.8% | 4.2% | 0.7% | 6.0% | 3.3% | 10.0% | −1.8% | 2.6% |
| EPS | −₹4.95 | ₹2.11 | ₹0.30 | ₹2.75 | ₹1.49 | ₹4.16 | −₹0.83 | ₹1.39 |
Dishman Carbogen Amcis financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹1,912 Cr | ₹2,141 Cr | ₹2,413 Cr | ₹2,616 Cr | ₹2,712 Cr | — |
| Operating profit | −₹43 Cr | ₹10 Cr | −₹6 Cr | −₹116 Cr | ₹37 Cr | — |
| Net profit | −₹165 Cr | ₹18 Cr | −₹30 Cr | −₹153 Cr | ₹3 Cr | — |
| EPS (₹) | −₹11.00 | ₹1.00 | −₹2.00 | −₹10.00 | ₹0.00 | — |
| Cash from operations | ₹513 Cr | ₹355 Cr | ₹220 Cr | ₹384 Cr | ₹375 Cr | — |
| Total debt | ₹504 Cr | ₹762 Cr | ₹1,047 Cr | ₹246 Cr | ₹1,149 Cr | ₹1,535 Cr |
| Shareholders' equity | ₹5,699 Cr | ₹5,549 Cr | ₹5,810 Cr | ₹5,628 Cr | ₹5,832 Cr | ₹6,677 Cr |
Dishman Carbogen Amcis shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% |
| Foreign institutions | 9.49% | 9.93% | 8.07% | 7.66% | 7.45% | 6.86% |
| Domestic institutions | 1.26% | 1.27% | 1.37% | 1.27% | 1.63% | 2.07% |
| Non-institutions | 29.93% | 29.47% | 31.23% | 31.75% | 31.60% | 31.75% |
Dishman Carbogen Amcis vs peers
The listed Pharma & Healthcare companies nearest to Dishman Carbogen Amcis by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ALEMBICLTDAlembic | ₹92.33 | +0.21% | −2.9% | ₹2,371 Cr | 7.5 | — |
| FREDUNFredun Pharmace | ₹1,376.10 | −0.35% | — | ₹2,276 Cr | 22.5 | — |
| DCALDishman Carbogen Amcis | ₹141.95 | +0.07% | −49.1% | ₹2,226 Cr | 22.8 | — |
| VIMTALABSVimta Labs | ₹495.55 | +2.15% | −28.3% | ₹2,214 Cr | 28.5 | — |
| MEDIASSISTMedi Assist Healthcare Services | ₹291.75 | −0.61% | −46.7% | ₹2,179 Cr | 24.1 | — |
| SYNCOMFSyncom Formulations (India) | ₹22.83 | +3.21% | +38.8% | ₹2,146 Cr | 28.2 | — |
| INDOCOIndoco Remedies | ₹230.55 | +0.74% | −21.9% | ₹2,128 Cr | — | — |
Ask anything about Dishman Carbogen Amcis
Pivot answers on the live chart with evidence you can check, and tests strategies against DCAL's own history. Try: “Why has DCAL moved over the last three months?” · “Backtest a 50-day moving-average crossover on DCAL over five years” · “Compare DCAL with ALEMBICLTD on margins and valuation”
Frequently asked questions about Dishman Carbogen Amcis
What is the share price of Dishman Carbogen Amcis today?
Dishman Carbogen Amcis (NSE: DCAL) last closed at ₹141.95 on 22 Oct 2026. Its 52-week high is ₹303.00 and its 52-week low is ₹128.50.
What is the market cap of Dishman Carbogen Amcis?
Dishman Carbogen Amcis' market capitalisation is ₹2,226 Cr (₹2,226 Cr) at the 22 Oct 2026 close, ranking 1100th among the NSE companies Pivot tracks.
What is the P/E ratio of Dishman Carbogen Amcis?
Dishman Carbogen Amcis trades at a trailing P/E of 22.8. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 24.1.
What is the ROE and ROCE of Dishman Carbogen Amcis?
Return on equity was 1.5% in FY26 and return on capital employed was 2.9% in FY26 (consolidated figures).
Is Dishman Carbogen Amcis a debt-free company?
No. Dishman Carbogen Amcis' debt-to-equity ratio was 0.42 in FY26, with total debt of ₹1,535 Cr.
What were Dishman Carbogen Amcis' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Dishman Carbogen Amcis reported revenue of ₹851 Cr, +18.9% year on year, and net profit of ₹22 Cr, −49.5% year on year.
How has Dishman Carbogen Amcis stock performed over the last year?
Dishman Carbogen Amcis' share price has fallen 49.1% over the past year, −23.3% over three months and −17.0% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Dishman Carbogen Amcis?
As of 30 Jun 2026: promoters 59.32%, foreign institutions 6.86%, domestic institutions 2.07%, non-institutions 31.75%.
Who are Dishman Carbogen Amcis' competitors?
The listed Pharma & Healthcare companies closest to Dishman Carbogen Amcis by market cap are Alembic, Fredun Pharmace, Vimta Labs, Medi Assist Healthcare Services, Syncom Formulations (India) and Indoco Remedies.
Is Dishman Carbogen Amcis a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Dishman Carbogen Amcis' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DCAL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with D · all NSE stocks · this page as text